sickle cell disease

Crizanlizumab helps prevent pain crises in sickle cell diseaseIn patients with sickle cell disease, therapy with crizanlizumab, an antibody against the adhesion molecule P-selectin, resulted in a significantly lower rate of sickle cell-related pain crises than placebo, a trial in 198 patients aged from 16 to 65 years showed.
Gene therapy could be ‘ultimate solution’ for sickle cell diseaseInvestigational gene therapies might reduce the suffering and death caused by this genetic disease.
Readers note inconsistencies in Puzzler caseReaders discuss some inconsistencies that they discovered in the February Puzzler, and the authors respond.
FDA drug approvals-April 2015FDA actions in brief, priority review, breakthrough therapy designation, fast-track designations, orphan drug designations, first-time generic approvals
Legally Speaking: Tubal ligation failure results in wrongful pregnancy claim
Legally Speaking: Tubal ligation failure results in wrongful pregnancy claimSix months after a tubal ligation, a woman became pregnant. She gave birth by cesarean to a child who was diagnosed with sickle cell disease.
Choking and cyanosis in an infant with sickle cell diseaseA 2-month-old African American girl who presented to the emergency department with 2 episodes of apnea or gasping respirations associated with feeds is admitted by your general inpatient pediatric service.
Sickle cell disease in pregnancy
Sickle cell disease in pregnancyPregnancy is risky for women with sickle cell disease. This overview examines concerns for the mother and fetus to help you manage the risks.
New treatment guidelines for sickle cell diseaseExpand treatment of sickle cell disease with 2 “underused” preventive therapies to reduce painful flare-ups, an expert panel convened by the National Heart, Lung, and Blood Institute urges in new management guidelines.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.
New clinical guidelines for treatment of SCDAn expert panel of specialists from the National Heart, Lung, and Blood Institute has issued new guidelines for the management and treatment of sickle cell disease (SCD). How will these latest evidence-based recommendations affect the care of your patients?